Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6544
    +0.0020 (+0.31%)
     

  • OIL

    84.37
    +0.80 (+0.96%)
     

  • GOLD

    2,356.70
    +14.20 (+0.61%)
     

  • Bitcoin AUD

    97,776.34
    +1,100.18 (+1.14%)
     

  • CMC Crypto 200

    1,378.39
    -18.15 (-1.30%)
     

  • AUD/EUR

    0.6104
    +0.0031 (+0.51%)
     

  • AUD/NZD

    1.0986
    +0.0029 (+0.26%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,601.70
    +171.19 (+0.98%)
     

  • FTSE

    8,123.06
    +44.20 (+0.55%)
     

  • Dow Jones

    38,126.38
    +40.58 (+0.11%)
     

  • DAX

    18,087.30
    +170.02 (+0.95%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

How Important Is Novavax's COVID Vaccine Manufacturing Deal With GlaxoSmithKline?

Keith Speights and Brian Orelli, PhD, The Motley Fool
·3-min read

GlaxoSmithKline (NYSE: GSK) has teamed up with several other companies to develop COVID-19 vaccine candidates. In this Motley Fool Live video, recorded on March 31, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss how important this manufacturing deal with GlaxoSmithKline is for Novavax. Keith Speights: Novavax -- the ticker there is NVAX -- announced this week that it's teamed up with GlaxoSmithKline -- ticker there is GSK -- to support the manufacturing of its COVID vaccine in the United Kingdom.

Continue reading